3 pharma stocks to watch in April

Pharma stocks are rarely a bad bet in the long term, but risk can vary widely and should be weighed judiciously on a case-by-case basis.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Merck & Co. (NYSE: MRK) is the archetypal pharma stock, providing solid returns over the long term, and is a real veteran of the industry, having survived a number of patent cliffs. Despite steady revenue growth and consistently growing dividend increases, Merck & Co.’s share price has been relatively flat this year and not entirely representative of all the good things the company has to offer in my opinion as a shareholder. The immuno-oncology (IO) treatment Keytruda is the company’s lynch-pin, bringing in 30% of annual revenue, and is an integral component of a multitude of pipeline regimens under investigation. Much like other similarly diversified companies, Merck & Co. is looking to improve its operating margin, in this case by spinning out the company’s women’s health and biosimilar divisions –historically slower growing than the core business.

Positive outlook, but things need to keep going right

AbbVie (NYSE: ABBV) has and continues to be heavily reliant on Humira, which was responsible for 40% of 2020 revenue, and competes against biosimilars in Europe. Biosimilar entry in the US is anticipated in 2023, and the expectation is that Humira sales will take a further substantial hit. So why is the outlook positive for this pharma stock?

AbbVie’s $63 billion acquisition of Allergan in May 2020 was met by the market with a degree of concern, but there is little doubt that it offered AbbVie some much needed diversification. More notably, however, AbbVie has developed two products that look set to secure its leadership position in immunology in a post-Humira world. Skyrizi and Rinvoq have shown strong uptake in their initial approved indications (psoriasis and rheumatoid arthritis, respectively), and AbbVie is vigorously pursuing additional indications, which should come through in the next 24 months. However, Rinvoq’s approvals for psoriatic arthritis and atopic dermatitis have each been pushed back by a quarter this year, owing to regulatory delays as the FDA investigates safety concerns related to the JAK-inhibitor class.  

A high-risk bet that should pay off in the short term (unless it doesn’t)

Over a decade ago, plucky upstart Amarin (NASDAQ: AMRN) gained FDA-approval for Vascepa, to treat patients with severely elevated triglycerides – a form of cholesterol that contributes to cardiometabolic disease. So far, so uneventful. Fast-forward to December 2019, and the label for Vascepa was expanded to include patients at high cardiovascular risk – effectively growing the potential market for the drug many-fold. Amarin’s share price sky-rocketed, at a rate rarely seen in mature pharma stocks. However, a court ruling in March 2020 in favour of generics challengers caused Amarin’s share price to plummet to a level it has never recovered from.

With the US market for Vascepa no longer the cake-walk it should have been, all eyes are now on Europe. Vascepa received EMA approval for the expanded indication in March of this year, and is set to launch first in Germany. The absence of generic competition, Vascepa’s first-in-class approval for a demonstrably large patient pool, and robust clinical outcomes data all paint a rosy picture. The risk lies in Amarin’s ability to pull it off, as a relatively small, US-based company with no other in-line products, and a handful of generics challengers snapping at its heels in its home-market of the US.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Pam Narang holds shares in Merck & Co. and Amarin. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

US Stock

The Nvidia share price falls! Here’s what I think happens next for the S&P 500

Jon Smith reviews the overnight results from Nvidia and explains why this could stall the S&P 500 performance through to…

Read more »

Investing Articles

Down 15% today, is this FTSE 100 share too cheap for me to miss?

JD Sports' share price has tanked after the FTSE 100 share released another profit warning. Is this the opportunity I've…

Read more »

Investing Articles

Up 8% today, is this FTSE 100 growth stock a slam-dunk buy for me?

Halma's share price is soaring thanks to another headline-grabbing trading update. Is the FTSE 100 stock now too good for…

Read more »

Investing Articles

With a P/E ratio of just 10.5 is now a brilliant time to buy a cut-price FTSE 250 tracker?

Harvey Jones says a recent dip in the FTSE 250 leaves the index trading at bargain levels. One stock in…

Read more »

Warren Buffett at a Berkshire Hathaway AGM
Investing Articles

To build a passive income flow, I’d follow this Warren Buffett approach

Warren Buffett has set up passive income streams most people can only dream about. Our writer sees some practical lessons…

Read more »

Growth Shares

As the boohoo share price falls, could it become a penny stock in 2025?

Jon Smith outlines some of the recent problems involving the boohoo share price and considers if things could get even…

Read more »

Young Asian woman with head in hands at her desk
Investing Articles

Here are the worst-performing FTSE 100 shares over the last 5 years

These five FTSE 100 shares have been complete duds over the last half decade. But is there potential for a…

Read more »

Investing Articles

Nvidia stock has tripled this year! Can it keep rising?

Nvidia's latest sales update showed strong growth and the stock's been on a tear so far in 2024. So is…

Read more »